ConductScience.org, home

Comparison · NCT05823012-d7430470

All Participants vs Participants Who Entered the Maintenance Period: Proportion of Participants With Normalized TSH Throughout the Maintenance Period

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. All Participants vs Participants Who Entered the Maintenance Period: Proportion of Participants With Normalized TSH Throughout the Maintenance Period. Trial comparisons, record NCT05823012-d7430470. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05823012-d7430470

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.5870.4430.717wilson
Risk in group 20.6430.4920.77wilson
Risk difference, group 1 minus group 2-0.0559-0.2480.144newcombe hybrid score
Risk ratio, group 1 over group 20.9130.6561.27log
Odds ratio, group 1 over group 20.7890.3331.87log
Number needed to treat, for one fewer participant with the outcome on All Participants than on Participants Who Entered the Maintenance Period17.9from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1All ParticipantsAll participants who received at least 1 dose of XP-8121 (100 to 1500 μg subcutaneous injection).2746OG000
Group 2Participants Who Entered the Maintenance PeriodAll participants who received XP-8121 (100 to 1500 μg subcutaneous injection), completed the Titration Period, and entered the Maintenance Period.2742OG001

Outcome

Type
SECONDARY
Title
Proportion of Participants With Normalized TSH Throughout the Maintenance Period
Description
Proportion of participants enrolled with normalized TSH throughout the Maintenance Period
Time frame
Day 29 of the Maintenance Period
Population

Source ClinicalTrials.gov

Trial

Title
Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
NCT number
NCT05823012
Phases
PHASE2
Conditions
Hypothyroidism
Interventions
levothyroxine sodium
Lead sponsor
Xeris Pharmaceuticals
Results first posted
2025-07-03

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT05823012-d7430470